MXPA02004480A - Metodos para identificar y utilizar compuestos inhibidores de amiloides. - Google Patents
Metodos para identificar y utilizar compuestos inhibidores de amiloides.Info
- Publication number
- MXPA02004480A MXPA02004480A MXPA02004480A MXPA02004480A MXPA02004480A MX PA02004480 A MXPA02004480 A MX PA02004480A MX PA02004480 A MXPA02004480 A MX PA02004480A MX PA02004480 A MXPA02004480 A MX PA02004480A MX PA02004480 A MXPA02004480 A MX PA02004480A
- Authority
- MX
- Mexico
- Prior art keywords
- ovx
- levels
- abeta
- guinea pigs
- amyloid
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 210000004556 brain Anatomy 0.000 abstract 4
- 241000700198 Cavia Species 0.000 abstract 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 102400000573 Amyloid-beta protein 40 Human genes 0.000 abstract 1
- 102400000574 Amyloid-beta protein 42 Human genes 0.000 abstract 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 abstract 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 abstract 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 abstract 1
- FEWOUVRMGWFWIH-ILZZQXMPSA-N amyloid-beta polypeptide 40 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 FEWOUVRMGWFWIH-ILZZQXMPSA-N 0.000 abstract 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 1
- 230000003942 amyloidogenic effect Effects 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960005309 estradiol Drugs 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000009806 oophorectomy Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pathology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16381999P | 1999-11-05 | 1999-11-05 | |
| PCT/US2000/030310 WO2001035106A2 (en) | 1999-11-05 | 2000-11-03 | Methods for identifying and using amyloid-inhibitory compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02004480A true MXPA02004480A (es) | 2004-09-10 |
Family
ID=22591720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02004480A MXPA02004480A (es) | 1999-11-05 | 2000-11-03 | Metodos para identificar y utilizar compuestos inhibidores de amiloides. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20080085244A1 (https=) |
| EP (1) | EP1272853A2 (https=) |
| JP (2) | JP2003522737A (https=) |
| AR (1) | AR027878A1 (https=) |
| AU (2) | AU2005200176B2 (https=) |
| CA (1) | CA2390161A1 (https=) |
| MX (1) | MXPA02004480A (https=) |
| NZ (3) | NZ543850A (https=) |
| TW (3) | TWI265026B (https=) |
| WO (1) | WO2001035106A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6815175B2 (en) | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
| BR0208165A (pt) * | 2001-03-16 | 2004-03-30 | Wyeth Corp | Composições farmacêuticas e seus usos na terapia de reposição de estrogênio |
| WO2008150547A1 (en) | 2007-06-04 | 2008-12-11 | The Regents Of The University Of California | Pregnancy hormone combination for treatment of autoimmune diseases |
| US20130203722A1 (en) | 2006-09-26 | 2013-08-08 | Rhonda R. Voskuhl | Estriol therapy for autoimmune and neurodegenerative disease and disorders |
| US6936599B2 (en) | 2001-04-25 | 2005-08-30 | The Regents Of The University Of California | Estriol therapy for multiple sclerosis and other autoimmune diseases |
| EP1371986A1 (en) * | 2002-06-06 | 2003-12-17 | ABETA GmbH | Diagnosis of Alzheimer's disease based on the hAbeta42:hAbeta40 ratio |
| JP2007284351A (ja) * | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
| CA2623839C (en) * | 2005-09-26 | 2013-12-17 | The Regents Of The University Of California | Estriol therapy for autoimmune and neurodegenerataive diseases and disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4311870C2 (de) * | 1993-04-10 | 1998-07-30 | Altramed Holdings Ltd | Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen |
| US5554601A (en) * | 1993-11-05 | 1996-09-10 | University Of Florida | Methods for neuroprotection |
| US5552415A (en) * | 1993-12-21 | 1996-09-03 | Eli Lilly And Company | Method of inhibiting Alzheimer's Disease |
| JP3552272B2 (ja) * | 1994-05-27 | 2004-08-11 | 帝国臓器製薬株式会社 | 免疫化学的簡易アッセイ方法および装置 |
| WO1997046664A1 (en) * | 1996-06-06 | 1997-12-11 | University Of Washington | Perlecan transgenic animals and methods of identifying compounds for the treatment of amyloidoses |
| JPH1090261A (ja) * | 1996-08-23 | 1998-04-10 | Fuotoreru Patrick | 性ステロイドホルモン測定用プレート、これを用いた測定キット及び測定法 |
| US5898094A (en) * | 1996-10-21 | 1999-04-27 | University Of South Florida | Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes |
| WO1998043647A1 (en) * | 1997-03-28 | 1998-10-08 | Massachusetts Institute Of Technology, Inc. | Regulation of amyloid precursor protein (app) expression by estrogenic compounds |
| WO1998048784A2 (en) * | 1997-04-28 | 1998-11-05 | The University Of British Columbia | Method and composition for modulating amyloidosis |
| US6080778A (en) * | 1998-03-23 | 2000-06-27 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
-
2000
- 2000-11-01 AR ARP000105767A patent/AR027878A1/es unknown
- 2000-11-03 MX MXPA02004480A patent/MXPA02004480A/es not_active Application Discontinuation
- 2000-11-03 EP EP00976880A patent/EP1272853A2/en not_active Withdrawn
- 2000-11-03 CA CA002390161A patent/CA2390161A1/en not_active Abandoned
- 2000-11-03 AU AU2005200176A patent/AU2005200176B2/en not_active Ceased
- 2000-11-03 NZ NZ543850A patent/NZ543850A/en unknown
- 2000-11-03 AU AU14592/01A patent/AU779781B2/en not_active Ceased
- 2000-11-03 WO PCT/US2000/030310 patent/WO2001035106A2/en not_active Ceased
- 2000-11-03 NZ NZ518780A patent/NZ518780A/en unknown
- 2000-11-03 JP JP2001536585A patent/JP2003522737A/ja active Pending
- 2000-11-03 NZ NZ536461A patent/NZ536461A/en unknown
-
2001
- 2001-02-16 TW TW089123307A patent/TWI265026B/zh not_active IP Right Cessation
- 2001-02-16 TW TW095101005A patent/TWI302099B/zh not_active IP Right Cessation
- 2001-02-16 TW TW097114203A patent/TW200834074A/zh unknown
-
2007
- 2007-11-01 JP JP2007285586A patent/JP2008058329A/ja active Pending
- 2007-12-07 US US11/952,531 patent/US20080085244A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001035106A3 (en) | 2002-11-14 |
| AU1459201A (en) | 2001-06-06 |
| NZ536461A (en) | 2005-02-25 |
| NZ518780A (en) | 2006-02-24 |
| US20080085244A1 (en) | 2008-04-10 |
| AU2005200176A1 (en) | 2005-02-10 |
| AR027878A1 (es) | 2003-04-16 |
| TWI302099B (en) | 2008-10-21 |
| TW200834074A (en) | 2008-08-16 |
| TW200621221A (en) | 2006-07-01 |
| WO2001035106A2 (en) | 2001-05-17 |
| NZ543850A (en) | 2009-03-31 |
| CA2390161A1 (en) | 2001-05-17 |
| AU2005200176B2 (en) | 2007-10-25 |
| JP2008058329A (ja) | 2008-03-13 |
| TWI265026B (en) | 2006-11-01 |
| JP2003522737A (ja) | 2003-07-29 |
| EP1272853A2 (en) | 2003-01-08 |
| AU779781B2 (en) | 2005-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60045427D1 (de) | Bupropinmetaboliten zur Behandlung von Dementia und anderen zerebrovasckulären Erkrankungen | |
| BR0114054A (pt) | Método para tratar alergias usando pirazóis substituìdos | |
| EA200200847A1 (ru) | Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов | |
| WO2004037204A3 (en) | Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease | |
| DE60237917D1 (de) | Gfats als modifikatoren des p53-wegs und verwendungsverfahren | |
| EA200101251A1 (ru) | Предотвращение и терапия амилоидогенной болезни | |
| CR8095A (es) | Anticuerpos humanizados que reconocen el cuerpo beta amiloideo | |
| EP1651164A4 (en) | COMPOSITION AND METHOD FOR THE TREATMENT OF NEUROLOGICAL ILLNESSES | |
| MXPA02004480A (es) | Metodos para identificar y utilizar compuestos inhibidores de amiloides. | |
| ATE544460T1 (de) | Zusammensetzungen und verfahren für eine gesunde schwangerschaft | |
| ATE429645T1 (de) | Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten | |
| WO2003068944A3 (en) | METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α- | |
| ATE299860T1 (de) | Vebindungen zur modulation des rage-rezeptors | |
| EA200300027A1 (ru) | Способ лечения сердечно-сосудистых заболеваний | |
| AR036401A1 (es) | Incremento de la cantidad de celulas madre neuronales inducido por prolactina. | |
| ATE329588T1 (de) | Verwendung von sibutramin zur behandlung von von organischen störungen verursachten zns- erkrankungen | |
| UA70925C2 (uk) | Спосіб лікування естрогенстимульованого раку | |
| AR055649A1 (es) | Metodo de mejora de la funcion cognitiva | |
| ATE515268T1 (de) | Verwendung von op-1 zur behandlung von knorpeldefekten | |
| ATE415163T1 (de) | Verfahren und zusammensetzungen zur behandlung von augenerkrankungen | |
| DE60204067D1 (de) | Verwendung von Xanthenon-4-Essigsäure zur Herstellung eines Medikaments für die Behandlung von hyperproliferativer Störungen | |
| DE69918145D1 (de) | Verwendung von diltiazem zur behandlung von pathologien der netzhaut | |
| EA200601547A1 (ru) | Применение модуляторов и ингибиторов tweak для лечения неврологических состояний | |
| DE60326742D1 (de) | Piperazin und piperadin-derivate für die behandlung von neurologischen krankheiten | |
| ATE345121T1 (de) | Verwendung von konjugierter linolsäure zur behandlung der erkältung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |